Prevalence of drug resistance under the DOTS strategy in Hyderabad, South India, 2001-2003

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 1, 2006, Pages 58-62

  Anuradha, B ^a   Priya, V H S ^a   Lakshmi, V V ^a   Akbar, Y ^a   Aparna, S ^b   Latha, G S ^a   Murthy, K J R ^a  

^a Bhagwan Mahavir Medical Research Centre   (India)

^b LEPRA Society   (India)

Author keywords

DOTS strategy; Multidrug resistant tuberculosis (MDR TB)

Indexed keywords

ISONIAZID; RIFAMPICIN;

ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; INDIA; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; SPUTUM SMEAR; TREATMENT OUTCOME; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; HUMANS; INDIA; PREVALENCE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 33144469448     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Quy HTW, Lan NTN, Borgdorff M W, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard retreatment regimen adequate? Int J Tuberc Lung Dis 2003; 7: 631-636.
2. Farmer P, Kim J. Community based approaches to the control of multi-drug resistant tuberculosis: introducing 'DOTS-Plus'. Brit Med J 1998; 317: 641-674.
3. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 375-382.
4. World Health Organization. Drug-resistant tuberculosis levels ten times higher in Eastern Europe and central Asia. WHO/ PR17. Geneva, Switzerland: WHO, 16 March 2004. www.who. int/mediacentre/news/releases/2004/pr17/en/ Accessed January 2005.
5. Chauhan L S. Status Report on RNTCP. Indian J Tuberc 2004; 51: 169-171.
6. Central TB Division. Involvement of private practitioners in the Revised National Tuberculosis Control Policy. New Delhi, India: Ministry of Health and Family Welfare, Central TB Division, 2000.
7. Murthy K J R, Frieden T, Yazdani A, Hreshikesh P. Public-private partnership in tuberculosis control: experience in Hyderabad, India. Int J Tuberc Lung Dis 2001; 5: 354-359.
8. Venkataraman P, Paramasivan C N (Compiled by). Drug susceptibility tests. Bacteriological Methods. New Delhi, India: Tuberculosis Research Centre, Indian Council for Medical Research, 2002: 61-73.
9. Jain N K, Chopra K K, Prasad G. Initial and acquired INH and rifampicin resistance to Mycobacterium tuberculosis and its implication for treatment. Indian J Tuberc 1992; 39: 180-186.
10. Paramasivan C N, Bhaskaran K, Venkataraman P, Chandrasekaran V, Narayanan P R. Surveillance of drug resistance in tuberculosis in the state of Tamil Nadu. Indian J Tuberc 2000; 47: 27-33.
11. Malhotra B, Pathak S, Vyas L, et al. Drug susceptibility profiles of Mycobacterium tuberculosis isolates at Jaipur. Indian J Med Microbiol 2002; 20: 76-78.
12. Paramasivan C N, Venkataraman P, Chandrasekaran V, Bhat S, Narayanan P R. Surveillance of drug resistance in tuberculosis in two districts of South India. Int J Tuberc Lung Dis 2002; 6: 479-484.
13. World Health Organization/International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world. Third Global Report. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance, 1999-2002. WHO/HTM/TB/2004.343. Geneva, Switzerland: WHO, 2004.
14. Paramasivan C N, Venkataraman P. Drug resistance in tuberculosis in India. Indian J Med Res 2004; 120: 377-386. [Review Article]
15. Mahadeo B, Kumar P, Agrawal S P, Chauhan LS, Sriknataramu N. Surveillance of drug resistance to anti- tuberculosis drugs in districts of Hoogli in West Bengal and Myurbhanj in Orissa. Indian J Tuberc 2005; 52: 5-10.
16. Datta M, Radhamani M P, Selvaraj R, et al. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. Tubercle Lung Dis 1993; 74: 180-186.
17. Chowgule R V, Deodhar L. Pattern of secondary acquired drug resistance to antituberculosis drug in Mumbai, India: 1991-1995. Indian J Chest Dis Allied Sci 1998; 40: 23-31
18. Migliori G B, Centis R, Fattorini L, et al. Mycobacterium tuberculosis complex drug resistance in Italy. Emerg Infect Dis 2004; 10: 752-753.
19. World Health Organization/International Union Against Tuberculosis and Lung Disease Global Working Group on anti tuberculosis drug resistance surveillance. Guidelines for surveillance of drug resistance in tuberculosis. WHO/TB/96.216. Geneva, Switzerland: WHO, 1996.
20. Espinal M A, Laserson K, Camacho M, et al. Determinants of drug resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5: 887-893.
21. + macrophages at the site of pleural tuberculosis coinfection. J Infect Dis 2001; 184: 1127-1133.
22. Nunes E A, De Capitani E M, Coelho E, et al. Patterns of anti-tuberculosis drug resistance among HIV-infected patients in Maputo, Mozambique, 2002-2003. Int J Tuberc Lung Dis 2005; 9: 494-500.
23. Pfyffer G E. Antimicrobial susceptibility testing in the management of multidrug-resistant tuberculosis. Vienna, Austria: IAPAC Symposium, 1999. www.aegis.com/pubs/iapac/2000/ IA000206.html Accessed January 2005.
24. Simone P M, Dooley S W. Multidrug-resistant tuberculosis, 1994. Atlanta, GA: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, 1994. http://www.cdc. gov/nchstp/tb/pubs/mdrtb/mdrtb.htm Accessed January 2005.
25. Khatri G R, Frieden T R. Controlling tuberculosis in India. N Engl J Med 2002; 347: 1420-1425.
26. Agarwal S P. New challenges in implementation of RNTCP in India. [Editorial] Indian J Tuberc 2005; 52: 1-4.